Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DO-2 in Patients With Advanced or Refractory Solid Tumours
NCT05752552Phase 1Recruiting
- Sponsor
- DeuterOncology
- Start
- Dec 2022
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of do-2 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by DeuterOncology. Primary endpoint: Treatment-Related Adverse Events at 12 months. Started Dec 2022; status: recruiting.
02
Drugs
do-2
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05752552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05752552.